The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells

Background The Rho-kinase ROCK II plays a major role in the activation of hepatic stellate cells (HSC), which are the key profibrotic and contractile cells contributing to the development of chronic liver disease. Inhibition of ROCK II ultimately blocks the phosphorylation of the myosin light chain (MLC) and thus inhibits stress fibre assembly and cell contraction. We investigated the effects of the ROCK inhibitors Y-33075 as well as Y-27632 in murine and human hepatic stellate cells. Methods Primary isolated HSC from FVB/NJ mice and the immortalized human HSC line TWNT-4 were culture-activated and incubated with Y-27632 and Y-33075 (10nM to 10μM) for 24h. Protein expression levels were analyzed by Western Blots and transcriptional levels of pro-fibrotic markers and proliferative markers were evaluated using real-time qPCR. Migration was investigated by wound-healing assay. Proliferation was assessed by BrdU assay. Contraction of HSC was measured using 3D collagen matrices after incubation with Y-27632 or Y-33075 in different doses. Results Both Rho-kinase inhibitors, Y-27632 and Y-33075, reduced contraction, fibrogenesis and proliferation in activated primary mouse HSC (FVB/NJ) and human HSC line (TWNT-4) significantly. Y-33075 demonstrated a 10-times increased potency compared to Y-27632. Surprisingly, both inhibitors mediated a substantial and unexpected increase in migration of HSC in FVB/NJ. Conclusion ROCK inhibition by the tested compounds decreased contraction but increased migration. Y-33075 proved more potent than Y27632 in the inhibition of contraction of HSCs and should be further evaluated in chronic liver disease.

[1]  D. Ezhilarasan.  Endothelin-1 in portal hypertension: The intricate role of hepatic stellate cells , 2020, Experimental biology and medicine.

[2]  P. Kamath,et al.  Combination of phosphodiesterase‐5‐inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[3]  E. Crouchet,et al.  Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives , 2020, Cells.

[4]  E. Tapper,et al.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  P. Boor,et al.  Rho-kinase inhibitor coupled to peptide-modified albumin carrier reduces portal pressure and increases renal perfusion in cirrhotic rats , 2019, Scientific Reports.

[6]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[7]  D. Fisher,et al.  ROCK inhibitor enhances the growth and migration of BRAF‐mutant skin melanoma cells , 2018, Cancer science.

[8]  M. Xie,et al.  The Rho-associated kinase inhibitors Y27632 and fasudil promote microglial migration in the spinal cord via the ERK signaling pathway , 2018, Neural regeneration research.

[9]  J. Ladero,et al.  Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[10]  Aron Parekh,et al.  The ROCK isoforms differentially regulate the morphological characteristics of carcinoma cells , 2017, Small GTPases.

[11]  L. Du,et al.  Rho‐kinase inhibitor Y‐27632 facilitates the proliferation, migration and pluripotency of human periodontal ligament stem cells , 2017, Journal of cellular and molecular medicine.

[12]  D. Clegg,et al.  ROCK Inhibition Promotes Attachment, Proliferation, and Wound Closure in Human Embryonic Stem Cell–Derived Retinal Pigmented Epithelium , 2016, Translational vision science & technology.

[13]  K. Kaibuchi,et al.  Developing novel methods to search for substrates of protein kinases such as Rho-kinase. , 2015, Biochimica et biophysica acta.

[14]  C. Strassburg,et al.  Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis , 2015, Gut.

[15]  Hyun-Man Kim,et al.  ROCK Inhibition Activates MCF-7 Cells , 2014, PloS one.

[16]  S. Thanos,et al.  Opposing Signaling of ROCK1 and ROCK2 Determines the Switching of Substrate Specificity and the Mode of Migration of Glioblastoma Cells , 2013, Molecular Neurobiology.

[17]  T. Sauerbruch,et al.  HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. , 2012, Journal of hepatology.

[18]  K. Burridge,et al.  From mechanical force to RhoA activation. , 2012, Biochemistry.

[19]  V. Metlushko,et al.  Treatment with Y-27632, a ROCK Inhibitor, Increases the Proinvasive Nature of SW620 Cells on 3D Collagen Type 1 Matrix , 2012, International journal of cell biology.

[20]  S. P. Srinivas,et al.  Rho-Rho kinase pathway in the actomyosin contraction and cell-matrix adhesion in immortalized human trabecular meshwork cells , 2011, Molecular vision.

[21]  Zhe Zhang,et al.  Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549 , 2011, Medical oncology.

[22]  J. Prakash,et al.  Reduction of Fibrogenesis by Selective Delivery of a Rho Kinase Inhibitor to Hepatic Stellate Cells in Mice , 2011, Journal of Pharmacology and Experimental Therapeutics.

[23]  J. Prakash,et al.  Increased Liver Uptake and Reduced Hepatic Stellate Cell Activation with a Cell-Specific Conjugate of the Rho-kinase Inhibitor Y27632 , 2011, Pharmaceutical Research.

[24]  S. Adachi,et al.  Rho-kinase inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells. , 2011, European journal of pharmacology.

[25]  M. Ares,et al.  Purification of RNA using TRIzol (TRI reagent). , 2010, Cold Spring Harbor protocols.

[26]  Sijin Liu,et al.  Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. , 2009, Cancer research.

[27]  S. Friedman,et al.  Mechanisms of hepatic fibrogenesis. , 2008, Gastroenterology.

[28]  T. Hibi,et al.  Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis , 2007, Journal of gastroenterology and hepatology.

[29]  H. Mellor,et al.  Actin stress fibres , 2007, Journal of Cell Science.

[30]  A. Hopkins,et al.  Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[31]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[32]  Pascale G. Charest,et al.  Big roles for small GTPases in the control of directed cell movement. , 2007, The Biochemical journal.

[33]  T. Sauerbruch,et al.  Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis , 2006, Gut.

[34]  K. Kotoh,et al.  Fasudil hydrochloride hydrate, a Rho‐kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[35]  J. Couchman,et al.  The Rho kinases I and II regulate different aspects of myosin II activity , 2005, The Journal of cell biology.

[36]  A. Gressner,et al.  Isolation and culture of hepatic stellate cells. , 2005, Methods in molecular medicine.

[37]  L. Pearl,et al.  Regulation of protein kinases in insulin, growth factor and Wnt signalling. , 2002, Current opinion in structural biology.

[38]  M. Pinzani.  PDGF and signal transduction in hepatic stellate cells. , 2002, Frontiers in bioscience : a journal and virtual library.

[39]  S. Friedman,et al.  Transcriptional Regulation in Hepatic Stellate Cells , 2001, Seminars in liver disease.

[40]  G. Owens,et al.  Smooth Muscle Differentiation Marker Gene Expression Is Regulated by RhoA-mediated Actin Polymerization* , 2001, The Journal of Biological Chemistry.

[41]  P. Tangkijvanich,et al.  Wound‐induced migration of rat hepatic stellate cells is modulated by endothelin‐1 through rho‐kinase‐mediated alterations in the acto‐myosin cytoskeleton , 2001, Hepatology.

[42]  H. Nawata,et al.  A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. , 2000, Journal of hepatology.

[43]  H. Yee.  Rho directs activation‐associated changes in rat hepatic stellate cell morphology via regulation of the actin cytoskeleton , 1998, Hepatology.